Equity
€11.68bn ▲ 11.6%
Janssen Pharmaceutica has made a profit without a break since 2010.
Janssen Pharmaceutica
Lifetime
17 annual accounts with figures on one time axis, 49 filings since 1977peak €22.59bn (2024)
€21.79bn▼ 3.5%
lowest -€4.2m (2009)
€1.46bn▼ 44.5%
peak €12.24bn (2020)
€11.68bn▲ 11.6%
€9.34bn▼ 6.4%
peak 5,324.5 FTE (2025)
5,324.5 FTE▲ 2.2%
Board89 names since 2004all names
14 directorsBart Philips and 13 others
Owners2 names in the annual accounts
99.99%Johnson & Johnson and 1 other
Documentsfilings and deeds
22-06-202639 days before the deadline
2025financial year
Result from €2.63bn to €1.46bnResignation: Kris Sterkens (managing director) 22-127 directors appointed, 2 resignations 27-11Appointment: Robin Gommers (director) 03-11Powers of attorney: Hilde Claes, Pascal Hoorn and 45 others 21-10Dividend €250.0m
Key points
from the 2025 annual accountsResult
€1.46bn ▼ 44.5%
The result fell in 2025 from €2.63bn to €1.46bn.
Group
6 companies controlled
Heads a group. Known shareholders 100%.
Board
3 joined · 4 left
Board changed. Latest change 03-11-2026 · 14 in office.
Position in the sector
€1.46bn
Higher net result than 95% of companies in pharmaceuticals. Sector median €358,757 · 95 companies.
Public support
€42.7m awarded from 2022 to 2025
Flemish support, mostly Onderzoeksproject.
Standalone figures, without subsidiaries
Checked score
90
Excellent
Financially stronger than 53% of companies in pharmaceuticals (NACE 21)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 16 companies (NACE 21, large).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.2%● unchanged vs 12-2024
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025highest value
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026lowest value
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 1.23, cash €24.7m
lowers risk
Founded in 1934
Size: turnover €21.79bn, 5,324.5 FTE, total assets €21.58bn, files consolidated accounts
Equity €11.68bn (54.1% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21). It does better than 61% of them on solvency, 27% on liquidity, 80% on profitability and 43% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 321 companies had the same profile as Janssen Pharmaceutica has now. Each dot is one company, two years later.
97.5%
were still trading
2.5%
stopped another way
0.0%
went bankrupt
That fits the bankruptcy probability of Janssen Pharmaceutica itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 321 companies, not a prediction for Janssen Pharmaceutica. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €1,050,950,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.23 (1.18 in 2024), below the usual 1.5. Short-term debt is 35.7% and cash 0.1% of total assets. 45.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-06-2026, 39 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
39 days early
2024
42 days early
2023
49 days early
2022
48 days early
2021
41 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 44 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 19 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
and 9 others
- Johnson & Johnson 99.99%annual accounts 2025
- Johnson & Johnson International 0.01%annual accounts 2025
Shares in 9 companies, including J.C. GENERAL SERVICES and JANSSEN-CILAG S.p.A.
Board & ownershipRecent changes
Resignation: Tim De Kegel (director)
Appointment: Griet Vangheel (director) · Director discharge: Tim De Kegel · General meeting of 21-10-2026 · Gazette deed
Share transfer
Johnson & Johnson holds all the shares · Gazette deed
Environmental permit granted
Bouwen of herbouwen, Nieuwbouw of aanleggen · Provincie Antwerpen
Environmental permit granted
Nieuwbouw of aanleggen, Nieuwbouw van bijgebouwen, niet-overdekte lage constructies en andere handelingen · Machelen
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Janssen Pharmaceutica Beerse | €21,788.2m | 6.8% | 54.1% | 5,324.5 |
| GlaxoSmithKline Biologicals Rixensart | €7,439.8m | 35.2% | 55.9% | 8,371 |
| UCB PHARMA Anderlecht | €4,622.6m | 7.2% | 78.3% | 1,960.6 |
| PFIZER MANUFACTURING BELGIUM Puurs-Sint-Amands | €1,022.7m | 13.9% | 76.7% | 4,020.8 |
| UCB BIOPHARMA Anderlecht | €3,642.1m | 3.7% | 16.4% | 1,395.2 |
Grey: the largest companies of the sector (pharmaceuticals (NACE 21)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as Janssen Pharmaceutica: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €2.5bn and €21bn, founded between 1960 and 2013.
Official details
Source: KBO- Status
- Active since 23-10-1934Normal situation
- Registered office
- 11 active companies are registered at this addressSource: KBO register, as of 8 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 2 others
- Joint committees
- 100Auxiliary committee for blue-collar workers
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment units
- 2.104.895.9412250 Olen, since 01-01-1800
- 2.142.774.7382440 Geel, since 01-01-1945and 10 others
- Financial year end
- 31 December
- Peppol
- Reachable since 18-12-2025
Annual accounts 2025
- €21.58bn▲ 3.0%
- Employeeson 31-12-2025
- 5,572▲ 2.5%
- Filing
- Filed on 22-06-2026, 39 days before the end of the filing period
Companies linked to Janssen Pharmaceutica
Subsidiaries and holdings
Insights on Janssen Pharmaceutica
Janssen Pharmaceutica has existed since 1934. Turnover grew from €1.79bn in 2008 to €21.79bn in 2025 and staff from 4,082.3 to 5,324.5 full-time equivalents.
Johnson & Johnson holds all the shares. In 2024, five directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Janssen Pharmaceutica
- What is the company number of Janssen Pharmaceutica?
- The company number of Janssen Pharmaceutica is 0403.834.160. The VAT number is the same number with BE in front: BE 0403.834.160.
- Where is Janssen Pharmaceutica based?
- The registered office is at Turnhoutseweg 30, 2340 Beerse.Company details
- What does Janssen Pharmaceutica do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of Janssen Pharmaceutica?
- Janssen Pharmaceutica is a public limited company (NV).
- When was Janssen Pharmaceutica founded?
- Janssen Pharmaceutica was founded on 23-10-1934.
- Is Janssen Pharmaceutica still active?
- Yes, Janssen Pharmaceutica is an active enterprise in the KBO register.
- How many employees does Janssen Pharmaceutica have?
- Janssen Pharmaceutica had an average of 5,324.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Janssen Pharmaceutica fall under?
- In its 2025 annual accounts, Janssen Pharmaceutica states joint committees 100 (Auxiliary committee for blue-collar workers) and 207 (White-collar workers in the chemical industry).
- What is the turnover of Janssen Pharmaceutica?
- The turnover of Janssen Pharmaceutica was €21.79bn in financial year 2025, according to the filed annual accounts.
- Is Janssen Pharmaceutica profitable?
- In financial year 2025, Janssen Pharmaceutica made a profit of €1.46bn.
- Where can I find the annual accounts of Janssen Pharmaceutica?
- Janssen Pharmaceutica filed 84 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Janssen Pharmaceutica due?
- Janssen Pharmaceutica must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.